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Dysregulation of the mammalian target of rapamycin (mTOR) kinase pathway is centrally involved in a wide
variety of cancers and human genetic diseases. In mammalian cells, mTOR is part of two different kinase
complexes: mTORC1 composed of mTOR, raptor and mLST8, and mTORC2 containing mTOR, rictor, sin1
and mLST8. Whereas, mTORC1 is known to be a pivotal regulator of cell size and cell cycle control, the ques-
tion whether the recently discovered mTORC2 complex is involved in these processes remains elusive. We
report here that the mTORC1-mediated consequences on cell cycle and cell size are separable and do not
involve effects on mTORC2 activity. However, we show that mTORC2 itself is a potent regulator of mamma-
lian cell size and cell cycle via a mechanism involving the Akt/TSC2/Rheb cascade. Our data are of relevance
for the understanding of the molecular development of the many human diseases caused by deregulation of
upstream and downstream effectors of mTOR.
INTRODUCTION
The serine/threonine protein kinase mTOR (mammalian target
of rapamycin) is the central player within a signalling cascade
regulating a wide variety of different cellular functions. In
mammalian cells two structurally and functionally distinct
mTOR-containing complexes have been identiﬁed. mTORC1
(also known as the mTOR/raptor complex) contains raptor
(regulatory associated protein of mTOR) and mLST8 (also
known as GbL). Whereas the function of mLST8 is not
really clariﬁed, raptor regulates mTORC1 functioning as a
scaffold for recruiting mTORC1 substrates. The major sub-
strates of mTORC1 known so far are 4EBP1 (eukaryotic
initiation factor 4E binding protein-1) and p70S6K (ribosomal
p70S6 kinase), both regulators of mRNA translation.
mTORC1 phosphorylates and activates p70S6K at T389 to
activate the ribosomal protein S6 via phosphorylation at
S240/244 (1,2).
The only recently discovered kinase complex mTORC2
(mTOR/rictor complex) also contains the mLST8 protein, but
is marked by the rictor (rapamycin-insensitive companion of
mTOR), sin1 (stress-activated protein kinase-interacting
protein) and protor subunits in place of raptor. Rictor and sin1
appear to stabilize each other through binding, building the
structural foundation for mTORC2. mTORC2 phosphorylates
the oncogenic kinase Akt (also known as protein kinase B) at
S473. Downstream of the phosphatidylinositol-3-kinase
(PI3K), PDK1 (phosphoinositide-dependent kinase-1) phos-
phorylatesAktatT308,whatinconjunctionwiththemTORC2-
mediated phosphorylation of Akt drives full activation of this
kinase (3,4). Over 100 putative Akt substrates have been
reported, although only a few of them meet the criteria
suggested for the deﬁnition of a bonaﬁde Akt substrate (5).
Akt phosphorylates and blocks the inhibitory effects of the
complex of the two tuberous sclerosis gene products TSC1/
TSC2 towards Rheb (Ras homolog enriched in brain), which
is a potent regulator of mTORC1. In addition, PRAS40
(proline-rich Akt substrate 40 kDa) is phosphorylated by Akt
at T246 releasing its inhibitory effects on mTORC1. In
summary, Akt stimulates mTORC1 signalling by inhibiting
the function of tuberin and PRAS40 (3,6).
The growth of an organ or a whole organism is regulated by
a coordinated increase in cell number and in cell size. To
remain constant during proliferative conditions, both DNA
content and cell mass must double in the course of each cell
division cycle. Accordingly, although separable, cell cycle
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mass) are coordinated. In 2002 and 2004, Fingar et al. (7,8)
published their pioneering work showing that mTOR controls
mammalian cell size and cell cycle progression via its down-
stream targets p70S6K and 4EBP1. Since these studies were
performed before the discovery of two mTOR-containing
kinase complexes with different functions and using the
inhibitor rapamycin to block mTORC1 activity, two major
questions must be answered to clarify mTOR’s role in cell
cycle and cell size control: (i) Is the regulation of mTORC2
an essential component for mTORC1-mediated cell cycle
and/or cell size control? (ii) Is mTORC2 itself capable of reg-
ulating mammalian cell cycle and/or cell size?
Making use of non-transformed, non-immortalized primary
human ﬁbroblasts we found that (i) the mTORC1-mediated
consequences on cell cycle and cell size are separable and
do not involve effects on mTORC2 activity; (ii) In addition,
we report here for the ﬁrst time that mTORC2 is a potent reg-
ulator of mammalian cell size and cell cycle via a mechanism
involving Akt/TSC2/Rheb.
RESULTS
Rapamycin-mediated effects on mTORC1 on cell cycle
and cell size are separable and do not involve
effects on mTORC2 activity
Many of the signalling components of the mTOR cascade are
frequently deregulated in a wide variety of cancers and other
human diseases (9). Accordingly, it is not surprising that the
regulation of mTOR was reported to be different depending
on the transformation status of the used cell system (10).
Another problem of many mTOR studies is that they have
been performed with ectopically overexpressed components
of the mTOR cascade or using in vitro assay systems. All
experiments presented in this report have been performed
using primary, non-transformed, non-immortalized, diploid
human IMR-90 ﬁbroblasts (11) studying endogenous proteins.
Modulation of endogenous activities has exclusively been
obtained either via the widely used mTORC1 inhibitor rapa-
mycin or via speciﬁc short-interfering RNAs (siRNAs).
Endogenous mTORC1 and mTORC2 activities have been
studied by analysing their endogenous functional readouts
phospho-T389 p70S6K and phospho-S473 Akt, respectively.
First, we determined the optimal concentration of rapamy-
cin to block mTORC1 in our cell system. Titration exper-
iments revealed that low rapamycin concentrations blocked
mTORC1 but also induced endogenous Akt S473 phosphoryl-
ation. The latter phenomenon, which we observed in several
experiments in the study performed here (see below), is very
likely owing to the well known earlier described
mTORC1-induced feedback mechanism involving the inhibit-
ing phosphorylation of insulin receptor substrate 1 via p70S6K
(1–4). For the experiments in this study we decided to use
100 nM, because at this concentration mTORC1 is efﬁciently
blocked and rapamycin mediates its well-known cell cycle
effects with only minor effects on Akt phosphorylation
(Fig. 1A–C).
At this concentration rapamycin triggered a very efﬁcient
block of mTORC1 activity (detected by downregulation of
phospho-T389 p70S6K and by faster migration of p70S6K
protein) (Fig. 1A and F), but was without such effects on
mTORC2 activity (compare phospho-S473 Akt levels and
Akt protein migration) (Fig. 1A, C and F), strongly decreased
the amount of S-phase cells (Fig. 1B and G; P , 0.05) and
reduced cell size demonstrated by a shift detected on
Forward scatter (FSC) histograms (Fig. 1D and H; P ,
0.05). Here, it is important to note that whenever such a cell
size phenotype is detected, two questions must be answered.
(i) Does the cell size reduction occur in all cell cycle
phases? (ii) Is the observed cell size reduction really a result
of altered cell growth or just of an altered rate of cell cycle
progression? To allow investigation of the ﬁrst question
DNA was stained and two-dimensional contour blot analyses
of FSC versus DNA content were performed (12) (Fig. 1E
and I). Furthermore, from the cell populations analysed in
the two-dimensional contour blots, G0/G1 cells (2 N) and
G2/M cells (4 N) have been selectively gated and analysed
via FSC histograms (Fig. 1E, upper right panel), FSC mean
values (Fig. 1E, lower right panel) and the % of the gated
cells (Fig. 1E, under the lower right panel) are presented.
These data demonstrate that rapamycin’s effects on cell size
regulation are independent of the cell cycle. In addition, it is
proven that the two-dimensional contour blot analyses used
in this study provide a suitable approach to study cell size
effects over the cell cycle. With regard to the second question
one has to consider that FSC analyses of cells cultivated under
low proliferation conditions also suggest decreased cell size.
However, in these cases the decreased FSC is because of an
increased amount of G0/G1 cells within the cell population
rather than to real cell size reduction. To clarify this issue
we cultivated IMR-90 cells under low proliferation conditions
without refreshing the growth medium for 48 h. Two-
dimensional contour blot cell size analyses revealed that low
proliferation conditions only increased the amount of G0/G1
cells without any effects on cell size, whereas rapamycin trig-
gers a real size reduction of cells in all cell cycle phases
(Fig. 1I).
To further investigate the kinetics of rapamycin’s effects on
cell size and cell cycle progression, we performed a time-
course experiment. Whereas diminished mTORC1 activity
(phospho-T389 p70S6K) occurred already after half an hour
and the effects on cell size (FSC) started already early being
good visible after 8 h, the effects on cell cycle regulation
(detected by decreasing cyclin A and cyclin D1 protein
levels and by % S-phase cells) were hardly detectable before
24 h. Interestingly, in this experiment no negative effects on
the phosphorylation of Akt S473 were detected (Fig. 1J–L).
In this study, we performed the widely used analyses of
endogenous phosphorylated Akt S473 as functional readout
for mTORC2 activity. Especially for the here presented
study, important reasons for the usage of this approach
instead of in vitro kinase assays exist. (i) We wanted to
really study the endogenous activites in primary non-
immortalized non-transformed cells. (ii) Since it is known
that the intracellular localization of both, p70S6K and Akt,
is regulated, one cannot expect the in vitro usage of ectopic
p70S6K and Akt as substrates to really reﬂect the in vivo
endogenous availability of these substrates. (iii) Since it
could be that the availability of both, p70S6K and Akt, is
Human Molecular Genetics, 2009, Vol. 18, No. 17 3299Figure 1. mTORC1-mediated consequences on cell cycle and cell size are separable and do not involve effects on mTORC2 activity. (A) Logarithmically
growing non-transformed, non-immortalized IMR-90 ﬁbroblasts, derived from human fetal lung tissue, were treated with the mTOR inhibitor rapamycina t
ﬁnal concentrations ranging from 0.1 nM to 100 nM for 24 h. Control cells were treated with an equal volume of DMSO (vehicle). Total lysates were prepared
and analysed for the expression level of p70S6K and Akt as well as for the phosphorylation status at T389 and S473, respectively. (B) In addition, so treated cells
were stained with propidium iodide and cytoﬂuorometrically analysed for DNA distribution. Representative DNA proﬁles are presented (upper panel). The per-
centage of cells in G0/G1, S and G2/M is indicated (lower panel). (C) Phospho-Akt S473 signals detected in (A) were densitometrically scanned and normalized
to total Akt levels. (D) 100 nM rapamycin-treated IMR-90 cells derived from the same pool of cells as analysed in (A, B and C) were cytoﬂuorometrically inves-
tigated for overall cell size via FSC (Forward Scatter) analyses. Overlays of FSC histograms are presented to enable direct comparison of control cells versus
rapamycin-treated cells (left panel). Mean FSC values obtained from these analyses are presented (right panel). (E) In addition, cell size according to different
cell cycle phases was examined via two-dimensional contour blot analyses of FSC versus DNA content. To visualize FSC shifts between different samples, a
crosshair has been set into the center of the G0/G1 population of control cells (left panel). For details regarding different types of FSC analyses compare the
Methods section in the text. Furthermore, G0/G1-phase cells (2 N) and G2/M-phase cells (4 N) were selectively gated and analysed for cell size distribution via
FSC. Mean FSC values and the percentage of gated cells are presented (right panel). (F) Lysates of IMR-90 cells treated with 100 nM rapamycin for the indicated
times were analysed for the expression level of total p70S6K (on long exposures the used a-p70S6K antibody recognizes also lower migrating p85S6K) and total
Akt as well as for their phosphorylated forms as indicated. In addition, same lysates were examined for cyclin A levels. (G) Logarithmically growing IMR-90
cells (vehicle) were either treated with 100 nM rapamycin for 24 h as described in (A) or were grown under low proliferation conditions. So treated cells were
cytoﬂuorometrically analysed for DNA distribution. The percentage of cells in S-phase is indicated. (H) In parallel, overall cell size was cytoﬂuorometrically
investigated via FSC (upper panel). Mean FSC values obtained from these analyses are presented (lower panel). (I) In addition, cell size according to different
cell cycle phases was examined via two-dimensional contour blot analyses of FSC versus DNA content. (J) IMR-90 ﬁbroblasts were treated with 100 nM rapa-
mycin for the indicated times and total cell lysates were analysed for the expression levels of p70S6K T389, total p70S6K, Akt S473, total Akt, cyclin A and
cyclin D1. In addition, the percentage of cells in S-phase was determined on the ﬂow cytometer. (K) Phospho-Akt S473 signals detected in (J) were densitome-
trically scanned and normalized to total Akt levels. (L) In parallel, overall cell size distribution of so treated cells was cytoﬂuorometrically analysed via FSC at
the indicated time points. (M) Logarithmically growing IMR-90 ﬁbroblasts were transfected with pooled short-interfering RNAs (siRNAs) targeting human rictor
(si rictor). Cells treated with non-targeting siRNAs (control) or cells which were left entirely untreated were analysed in parallel. About 72 h after initial transfec-
tion, lysates were prepared and analysed for indicated proteins via immunoblotting. (N) Experiments were basically performed as described in (M) with the
exception that cells were treated with 100 nM rapamycin or DMSO for the ﬁnal 24 h of incubation. So treated cells were lysed and examined for the expression
level of rictor, S473 phosphorylated Akt, total Akt, T389 phosphorylated p70S6K and total p70S6K.
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vitro usage of constitutive ectopic p70S6K and Akt as sub-
strates to really reﬂect the in vivo endogenous availability of
these substrates in all the cell cycle experiments. We per-
formed additional experiments to prove that analysing
endogenous phosphorylated Akt really reﬂects endogenous
mTORC2 activity under our experimental conditions in the
cell system used here. Compared with both non-treated cells
and cells transfected with non-targeting siRNAs, siRNAs
speciﬁc for the mTORC2 component rictor trigger downregu-
lation of endogenous Akt S473 phosphorylation (Fig. 1M).
This is even true in cells, in which mTORC1 activity has
been blocked via rapamycin (Fig. 1N). These ﬁndings demon-
strate that analysing endogenous levels of Akt S473 phos-
phorylation reﬂects a reliable and speciﬁc approach to study
endogenous mTORC2 activity in our cells.
Taken together, these data demonstrate that blocking
mTORC1 mediates cell size reduction in the cells of all cell
cycle phases and affects cell cycle regulation separable from
its cell size effects. Most importantly, all that occurs
without downregulation of mTORC2-mediated Akt S473
phosphorylation.
Blocking mTORC1 activity delays S-phase induction with
smaller G1 cells entering S but without effects on
mTORC2 activity
Cell growth in size is a requirement for cell proliferation, as
cells must double in size before dividing (13,14). From the
data obtained so far three questions arose: (i) Does blocking
of mTORC1 delay S-phase induction in primary non-
transformed, non-immortalized human cells? (ii) Is mTORC2
activity affected at any time point during the transition of
rapamycin-treated G1 cells into S phase? (iii) Do such cells
with blocked mTORC1 activity pass the G1–S phase transition
to start replication at smaller size?
To investigate these issues, IMR-90 cells were serum
arrested and restimulated with and without rapamycin
(Fig. 2A). The discovery that mTOR exists in two structurally
and functionally distinct kinase complexes and the observation
that under certain circumstances a rapamycin-mediated block
of mTORC1 is accompanied by effects on mTORC2-mediated
Akt phosphorylation (depending on the transformation status
of the analysed cell) (10,11) made it essential to also investi-
gate the role of mTORC2. Western blot analyses studying the
restimulated cells described above revealed that the
rapamycin-triggered block of mTORC1-mediated p70S6K
T389 phosphorylation leads to delayed S-phase induction
without any effects on mTORC2-mediated Akt S473
phosphorylation (Fig. 2B and C).
Four independent approaches—western blot analyses of
cyclin D1 and A, analysing DNA distribution, BrdU incorpor-
ation assays and cytochemical cyclin A analyses—revealed
that blocking mTORC1 activity via rapamycin indeed causes
a delay in S-phase entry for some hours (Fig. 2B–E).
FSC analyses and two-dimensional contour blot studies of
FSC versus DNA content demonstrated that rapamycin-treated
cells start to replicate at a smaller size compared with non-
treated counterparts (Fig. 3A and B). To additionally
conﬁrm this observation, we compared two time points
during restimulation from the experiment described in
Figure 2B and C with and without rapamycin with similar
G0/G1–S–G2/M phase distributions. Flowcytometric FSC
analyses of gated G0/G1 and of gated SþG2/M
phase cells revealed a pronounced difference in cell size at
the G1/S-phase transition between rapamycin-treated and non-
treated cells (Fig. 3C). In addition, we also compared two time
points during restimulation from the experiment described in
Figure 2D and E representing the ﬁrst strong BrdU incorpor-
ation in cells with and without rapamycin. Comparable
to the experiment described above, FSC analyses of gated
G0/G1 and of gated S þ G2/M phase cells again revealed a
pronounced difference in cell size at the G1/S-phase transition
between rapamycin-treated and non-treated cells (Fig. 3D;
P , 0.05). In summary, these ﬁndings prove that cells with
blocked mTORC1 activity indeed start to replicate later and
at a smaller cell size.
Taken together, our ﬁndings show for the ﬁrst time that
mTORC1 can control cell cycle progression and cell size in
cells without any effects on mTORC2 activity.
mTORC2 regulates mammalian cell size and cell cycle
progression
Next, we investigated the question whether the kinase
complex mTORC2 itself is capable of regulating mammalian
cell size and/or cell cycle. We made use of rictor- and raptor-
speciﬁc siRNAs to downregulate endogenous mTORC2 and
mTORC1 activities in primary non-transformed, non-
immortalized human ﬁbroblasts. As expected, knockdown of
rictor triggered downregulation of endogenous phospho-S473
Akt levels and the same is true for the effects of raptor-speciﬁc
siRNAs on endogenous phospho-T389 p70S6K levels
(Fig. 4A). Once again, these results prove that analysing the
phosphorylation status of these two substrates as endogenous
functional readouts is a speciﬁc and reliable approach to
study the endogenous activities of the two mTOR kinase
complexes. In agreement with earlier observations using
rapamycin to block mTORC1 activity (7,8) (Figs 1–3), down-
regulation of endogenous mTORC1 activity via raptor-speciﬁc
siRNAs mediated deregulation of cell cycle progression (from
56.2% to 83.3% G0/G1 cells and from 35.4% to 12.6% S
phase cells) (Fig. 4B; P , 0.05) and of size of cells in all
cell cycle phases (Fig. 4C and D; P , 0.05).
Interestingly, siRNA-mediated knockdown of rictor also
mediated strong effects on both, cell cycle progression (from
56.2% to 76.6% G0/G1 cells and from 35.4% to 18.8% S
phase cells) (Fig. 4B; P , 0.05) and cell size regulation
(Fig. 4C; P , 0.05). Two-dimensional contour blot analyses
of FSC versus DNA content revealed that mTORC2-induced
cell size regulation is not a consequence of its effects on
cell cycle progression since knockdown of rictor triggers a
size reduction in all cell cycle phases (Fig. 4D).
These experiments demonstrate mTORC2 (i) to be a potent
regulator of mammalian cell cycle progression; (ii) to be a
potent cell size regulator; and (iii) to be able to control size
of cells in all phases of the mammalian cell cycle.
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involving Akt/TSC2/Rheb
Next we wanted to obtain insights into the underlying molecu-
lar mechanism of how mTORC2 controls cell cycle pro-
gression and cell size in mammalian cells. The major
function of mTORC2 is to phosphorylate and thereby activate
Akt (3,4). So far, although many putative Akt substrates have
been reported, only very few of them meet all the criteria,
which have been deﬁned to be necessary to characterize a
bonaﬁde Akt substrate (5). Since mTORC1 is very well
known to be a pivotal regulator of both, cell cycle and cell
size control (1), Akt substrates, which are involved in
mTORC1 regulation were of special interest.
One Akt substrate playing a major role in mTORC1 regu-
lation is TSC2 (tuberin). TSC2 (in a complex with TSC1) is
phosphorylated by Akt on S939 and T1462 and this phos-
phorylation inhibits its ability to act as a GTPase-activating
Figure 2. Blocking mTORC1 activity delays S-phase induction without effects on mTORC2 activity. IMR-90 ﬁbroblasts, synchronized in G0/G1 via serum
deprivation, were serum restimulated to re-enter the cell cycle in the presence or absence of the mTOR inhibitor rapamycin. (A) Schematic outline of the syn-
chronization procedure. Brieﬂy, cells growing under full serum (10% FCS) conditions for 24–72 h were serum-deprived in medium containing 0.2% serum
(0.2% FCS) for 48 h and serum restimulated (10% FCS) for additional 36 h. Rapamycin was added 30 min prior to restimulation at a concentration of
100 nM. Control cells were treated with an equal volume of DMSO and analysed in parallel. (B) Cells treated as described in (A) were lysed and examined
for the expression level of cyclin D1, cyclin A, p70S6K T389, p70S6K, Akt S473 and Akt at the indicated time points via immunoblotting. (C) In addition,
cells were cytoﬂuorometrically analysed for DNA content at the indicated time points. DNA proﬁles are presented (upper panel). In addition, the percentage
of cells in S-phase was determined for DMSO (vehicle)- and rapamycin-treated cells. To facilitate interpretation of S-phase induction, a baseline corresponding
to the S-phase values of serum-deprived vehicle- and rapamycin-treated cells was inserted into the graph. (D) Experiments as described in (A, B and C) were
repeated and the percentage of cells actively undergoing DNA replication was analysed by immunocytochemical BrdU incorporation assay at speciﬁc time points
as indicated (at least 250 cells were scored for each timepoint). (E) In addition, cells derived from the same pool of cells as described in (D) were immunocy-
tocemically stained for cyclin A expression (at least 250 cells were scored for each timepoint).
3302 Human Molecular Genetics, 2009, Vol. 18, No. 17protein against Rheb, which in turn regulates mTORC1’s
potential to activate p70S6K (15–20) (Fig. 5A). Accordingly,
one could speculate that blocking mTORC2 activity could
trigger downregulation of mTORC1 via activation of TSC2.
In agreement with this model we found that modulation of
mTORC2 via rictor-speciﬁc siRNAs really, as a consequence,
Figure 3. Blocking mTORC1 activity causes G1 cells to enter S-phase at smaller size. IMR-90 ﬁbroblasts, synchronized and restimulated in the presence or
absence of 100 nM rapamycin as described in Figure 2, were analysed on a ﬂowcytometer. At speciﬁc time points as indicated, cells from the experiment pre-
sented in Figure 2B and C were examined for overall cell size via FSC analyses (A) (in addition, mean FSC values for each time point are presented in numbers)
and for cell size according to different cell cycle phases via two-dimensional analyses of FSC versus DNA content (B) (in addition, the percentage of cells in
S-phase is presented for each time point). (C) Cells from the experiment presented in Figure 2B and C were analysed in more detail. DMSO-treated cells
(vehicle) at 15 h restimulation were compared with rapamycin-treated cells at 27 h restimulation via two-dimensional FSC analysis (left panel). In addition,
G0/G1-phase cells and SþG2/M-phase cells were selectively gated and analysed for cell size distribution via FSC (upper right panel). Mean FSC values are
presented (lower right panel). (D) Rapamycin or vehicle-treated cells derived from the same experiment presented in Figure 2D and E were analysed as outlined
in (C) with the exception that DMSO-treated cells (vehicle) at 15 h restimulation were compared with rapamycin-treated cells at 24 h restimulation.
Human Molecular Genetics, 2009, Vol. 18, No. 17 3303triggers downregulation of mTORC1 activity in primary
human cells (Figs 1M, N, 4A and 5B). To clarify the role of
this pathway for mTORC2-mediated cell size and cell cycle
regulation, we ﬁrst wanted to investigate the effects of rictor-
speciﬁc siRNA treatment in cells with knockdown of TSC2.
Knockdown of TSC2 indeed reactivated mTORC1 activity
(represented by endogenous phospho-T389 p70S6K levels),
but not mTORC2 activity (endogenous phospho-S473 Akt
levels), in cells treated with rictor-speciﬁc siRNAs (Fig. 5B).
These results prove that the effects of downregulated
mTORC2 activity on mTORC1 are indeed mediated via the
TSC2-involving cascade. And strikingly, both mTORC2-
mediated effects on cell cycle (DNA analyses and investi-
gation of the cell cycle inhibitor p27) and cell size were sig-
niﬁcantly diminished upon TSC2 knockdown (Fig. 5C–F;
P , 0.05). Taken together, these ﬁndings provide strong evi-
dence that in mammalian cells mTORC2 controls both, cell
cycle progression and cell size, via its potential to regulate
TSC2.
The notion that mTORC1’s potential to regulate p70S6K
activity is involved in the mechanism of mTORC2’s effects
on cell size and cell cycle control was additionally supported
by studying the effects of knockdown of PRAS40. PRAS40 is
another Akt substrate being involved in mTORC1 regulation.
PRAS40 was identiﬁed as a raptor-binding protein, which
does not interact with mTORC2. It is also phosphorylated
directly by mTORC1, but not mTORC2, predominantly at
S183. Akt-mediated phosphorylation of PRAS40 at T246 pre-
vents its inhibition of mTORC1 (Fig. 5A). Importantly,
PRAS40 regulates mTORC1 via a totally different mechan-
ism compared with TSC2. PRAS40 functions as a direct
inhibitor of mTORC1 substrate binding (21–26). Accord-
ingly, in a cell in which mTORC1 kinase activity is downre-
gulated via the mTORC2/Akt/TSC2/Rheb cascade (presented
in Fig. 5A), one would not expect knockdown of PRAS40 to
reactivate mTORC1-mediated phosphorylation of p70S6K at
T389. Knockdown of PRAS40 might increase mTORC1’s
potential to bind to its substrates but would not reactivate
mTORC1-mediated p70S6K phosphorylation in a cell, in
which rictor-speciﬁc siRNA treatment triggers downregula-
tion of mTORC2-mediated Akt activity and activation of
TSC2 to block mTORC1’s kinase activity. In agreement
with this notion, we found knockdown of PRAS40 not be
able to reactivate mTORC1-induced T389 p70S6K phos-
phorylation in cells treated with rictor-speciﬁc siRNAs
(Fig. 5B). Our ﬁndings that modulating PRAS40 was
without consequences for mTORC2-dependent effects on
cell cycle and cell size regulation (Fig. 5C, E and F),
additionally support the here suggested model of mTORC2
controlling both, cell cycle progression and cell size, by reg-
ulating TSC2.
Our data presented so far provide strong evidence that
mTORC2 affects cell cycle and cell size regulation via modu-
lating the potential of TSC2 to regulate mTORC1. This poten-
tial of TSC2 is mediated via Rheb (compare also Fig. 5A). Our
ﬁndings suggest that knockdown of endogenous mTORC2
activity via rictor siRNAs allows TSC2 to efﬁciently block
Rheb’s activity to control mTORC1. In line with this assump-
tion, TSC2 should not be able to revert the effects of rictor
siRNA treatment on cell size in a Rheb-negative (-diminished)
background. First, transfection experiments proved that the
activating effects of TSC2-speciﬁc siRNAs on p70S6K
activity depend on functional Rheb (Fig. 6A). Furthermore,
we observed again that TSC2 siRNA treatment counteracts
the negative effects of rictor-speciﬁc knockdown on cell
size regulation. Cotransfection with Rheb-speciﬁc siRNAs
Figure 4. mTORC2 regulates mammalian cell size and cell cycle progression.
Logarithmically growing IMR-90 ﬁbroblasts were transfected with short-
interfering RNAs (siRNAs) targeting human raptor and rictor, respectively.
Cells treated with non-targeting siRNA were analysed in parallel and served
as a negative control (control). Forty-eight hours after transfection, cells
were replated at low density and were grown for another 20 h. (A) Cells as
described above were lysed and examined for the expression level of raptor,
rictor, S473 phosphorylated Akt, total Akt, T389 phosphorylated p70S6K
and total p70S6K. a-Tubulin was co-analysed as an additional loading
control. (B) Cells derived from the same pool of cells described in (A) were
cytoﬂuorometrically analysed for DNA distribution. Representative DNA pro-
ﬁles (upper panel) and the percentage of cells in G0/G1, S and G2/M (lower
panel) are presented. Apart from the quantiﬁcation of DNA distribution,
cells were cytoﬂuorometrically examined for overall cell size via FSC ana-
lyses (C) and for cell size according to different cell cycle phases via two-
dimensional blots of FSC versus DNA content (D).
3304 Human Molecular Genetics, 2009, Vol. 18, No. 17demonstrated that these TSC2-mediated effects also depend on
functional Rheb (Fig. 6A–D; P , 0.05).
As already described above, we assume that the effects of
mTORC2 on cell size depend on its potential to regulate the
Akt kinase: downregulating endogenous rictor leads to
diminshed Akt activity, what induces the cascade presented
in Figure 5A. Last but not least, to test whether Akt regulation
indeed represents the initial relevant step for the mTORC2-
mediated cell size control, we tested the effects of rictor-
speciﬁc siRNA treatment in cells expressing myristoylated
Akt. These experiments demonstrated that downregulation of
mTORC2 via rictor siRNAs cannot control mammalian cell
size in cells harboring constitutive Akt kinase activity
(Fig. 6E–H; P , 0.05).
In summary, our here described ﬁndings show that
mTORC2 regulates mammalian cell size via a mechanism
involving the Akt/TSC2/Rheb cascade.
DISCUSSION
In mammalian cells, the mTOR pathway has been shown to be
a pivotal regulator of both cell cycle progression and cell size.
Accordingly, studies have been performed before the discov-
ery that mTOR is also part of a second kinase complex
named mTORC2. In addition, in many of the underlying
experiments mTOR activity has been modulated via rapamy-
cin (see e.g. 7,8). Although originally believed to exclusively
block mTORC1, rapamycin has been shown to also affect
Figure 5. mTORC2 regulates cell size and cell cycle via a mechanism involving TSC2. (A) Simpliﬁed schematic presentation of the potential functional inter-
action of mTORC2 and mTORC1 in cell size regulation. Both, PI3K and mTORC2 (mTOR/rictor) are necessary to drive full activation of the serine-threonine
kinase Akt, which in turn negatively regulates PRAS40 and the TSC1/2 complex to activate mTORC1 (mTOR/raptor) known to exert positive effects on cell size
regulation via its effector S6K. (B–F) Logarithmically growing IMR-90 ﬁbroblasts were either transfected with rictor siRNA alone or were co-transfected with
siRNAs targeting rictor and PRAS40 or rictor and TSC2. Non-targeting siRNA (control) was analysed in parallel. Sixty hours post transfection, cells were
replated into fresh growth medium and incubated for additional 20 h. For experiments presented in (D), cells were transfected as described above but were
grown for a total of 96 h without replating. (B) siRNA-treated cells were harvested, lysed and protein levels of rictor, PRAS40 and tuberin were examined
via immunoblotting to prove efﬁcient knockdown of target proteins. In addition, the expression level of Akt and p70S6K as well as the corresponding phos-
phorylation status at S473 and T389, respectively, were analysed. Lysates of non-treated cells, which were co-analysed in parallel, were included to prove
the here used conditions of siRNA treatment to be physiologic and technically sound (compare control versus non-treated). (C) siRNA-treated cells derived
from the same pool of cells described in (B) were stained with propidium iodide and cytoﬂuorometrically analysed for cell cycle distribution. Representative
DNA proﬁles (upper panel) and the percentage of cells in G0/G1, S and G2/M (lower panel) are presented. (D) Lysates of cells treated as indicated were exam-
ined for the expression levels of rictor, tuberin, p27 and a-tubulin. In addition, cells were examined for overall cell size via FSC analyses (E) and for cell size
according to different cell cycle phases via two-dimensional blots of FSC versus DNA-content (F) on the ﬂow cytometer.
Human Molecular Genetics, 2009, Vol. 18, No. 17 3305mTORC2 activity at least under speciﬁc experimental con-
ditions (10,11). Accordingly, with regard to mTOR’s role in
cell size and cell cycle control in mammalian cells, two
major question remained elusive: (i) Is the regulation of
mTORC2 essentially involved in mTORC1-mediated cell
cycle and/or cell size control? (ii) Is mTORC2 itself capable
of regulating mammalian cell cycle and/or cell size?
To answer these questions we felt it to be essential to use an
optimal biological cell system. In the past, many data on
mTOR regulation were obtained from ectopic overexpression
experiments in transformed cells or using in vitro kinase
assays. Varying results on mTOR regulation have been reported
in many different immortalized or transformed cell lines, what
is mainly because of the fact that a wide variety of upstream
regulators of mTOR are deregulated in many different types
of diseases and tumors (3,9–11,27). All experiments presented
in this study have been performed using non-transformed, non-
immortalized primary human diploid IMR-90 ﬁbroblasts
harboring a ﬁnite lifetime and a normal karyotype (11). In
addition, with the exception of ectopic expression of myristoy-
lated Akt no overexpression experiment is included, but we
exclusively modulated endogenous activities.
Figure 6. The role of Rheb and Akt for mTORC2-mediated cell size effects. (A) IMR-90 cells were transfected with siRNAs targeting either TSC2, Rheb or
both. Lysates of so treated cells were examined for the expression levels of tuberin, phospho-p70S6K T389 and total p70S6K. A non-speciﬁc band (NB) serves as
a loading control. (B–D) IMR-90 ﬁbroblasts were either treated with rictor siRNA alone or were co-transfected with siRNAs targeting rictor and TSC2 or rictor,
TSC2 and Rheb, respectively. Cells were replated into fresh growth medium 60 h post transfection and incubated for additional 20 h. (B) So treated cells were
stained with propidium iodide and cytoﬂuorometrically analysed for overall cell size via FSC analyses. (C) Mean FSC values obtained from these analyses are
presented. (D) In addition, cell size according to different cell cycle phases was examined via two-dimensional blots of FSC versus DNA-content. (E–H) Rictor-
and control siRNA-treated cells were grown for 72 h, replated and transiently transfected with an empty expression vector or with an expression vector contain-
ing myristoylated (constitutively active) Akt (myrAkt) together with GFP-spectrin expression plasmids as reporter. Another 36 h later, cells were harvested and
analysed via immunoblotting and ﬂowcytometry. (E) The expression levels of rictor, ectopic Akt (via myc-antibody) and a-tubulin were analysed. (F)I n
addition, GFP-positive cells were examined for overall cell size via FSC analyses. (G) Corresponding mean FSC values obtained from these analyses are indi-
cated. (H) Cell size according to different cell cycle phases was examined via two-dimensional blots of FSC versus DNA content.
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cell cycle and cell size are separable (7,8). We have conﬁrmed
and expanded this knowledge: (i) The approach of two-
dimensional contour blot analyses of FSC versus DNA
content allowed the demonstration that blocking endogenous
mTORC1 via rapamycin reduces the size of cells in all cell
cycle phases. (ii) Identical results were obtained in cells, in
which endogenous mTORC1 was diminished via raptor-
speciﬁc siRNAs. (iii) Rapamycin time-course experiments
revealed that the effects of downregulated mTORC1 on cell
size occur far before the cell cycle deregulation. (iv)
Re-stimulation experiments with and without rapamycin
showed that blocking mTORC1 activity delays S-phase induc-
tion with smaller G1 cells starting to replicate.
Four independent experimental data support our conclusion
that mTORC1-mediated cell cycle regulation does not need to
involve effects on mTORC2 activity. (i) Rapamycin treatment
of logarithmically growing cells triggers accumulation of
G0/G1 cells accompanied by a downregulation of the
amount of S-phase cells without effects on endogenous
mTORC2 activity. (ii) A rapamycin time-course experiment
revealed that after 24 h blocking mTORC1 activity cyclin A
levels, cyclin D1 levels and % S-phase cells decreased, but
no effects could be detected on mTORC2 activity. (iii)
Serum re-stimulation approaches revealed that a rapamycin-
mediated block of mTORC1 signiﬁcantly delays S-phase
entry without any effects on mTORC2 activity. (iv) Downre-
gulation of endogenous mTORC1 activity via raptor-speciﬁc
siRNAs in logarithmically growing cells also triggered
accumulation of G0/G1 without negatively affecting
mTORC2. That mTORC2 deregulation is also not playing
an essential role for mTORC1-triggered cell size control was
demonstrated (i) by showing that rapamycin triggers size
reduction in all cell cycle phases of cycling cells without
affecting mTORC2; (ii) by obtaining the same results upon
blocking of mTORC1 via raptor-speciﬁc siRNAs; (iii) by
detecting deregulated cell size control in a rapamycin time-
course experiment without effects on endogenous mTORC2
activity; (iv) by demonstrating that rapamycin-treated cells
enter the replicative phase at smaller size but do not exhibit
any modulation of endogenous mTORC2 activity. In
summary, these ﬁndings allow the conclusion that in mamma-
lian cells mTORC1 can regulate cell cycle progression and
cell size control independent of any effects on endogenous
mTORC2 activity.
Next, we found that downregulating endogenous mTORC2
activity via rictor-speciﬁc siRNAs causes an accumulation of
G0/G1 cells accompanied by a decrease of S-phase cells.
Our here obtained data using primary non-transformed, non-
immortalized human ﬁbroblasts are in perfect agreement
with a recent study reporting the same cell cycle phenotype
upon knockdown of rictor in the MCF7 breast cancer and
PC3 prostate cancer cell lines (28), suggesting that this poten-
tial of mTORC2 might be independent of the transformation
status of the cell. Still, that mTORC2 itself is involved in
tumor development is suggested by the recent ﬁnding that
many gliomas overexpress rictor accompanied with elevated
mTORC2 activities (29).
Drosophila mutants removing the critical TORC2 com-
ponents, rictor and sin1, showed minor growth impairment
(30). The aspect whether mTORC2 is involved in mammalian
cell size regulation remained elusive so far. We report here
that siRNA-induced knockdown of endogenous mTORC2
activity triggers strong effects on cell size regulation of non-
transformed primary human cells. Several independent exper-
iments revealed that rictor-siRNA-mediated size reduction to
be comparable to the effects of a raptor-speciﬁc knockdown.
Two-dimensional contour blot analyses of FSC versus DNA
content demonstrated that mTORC2-mediated cell size regu-
lation is not a consequence of its effects on cell cycle pro-
gression described above. We found that knockdown of
rictor to trigger a size reduction in all cell cycle phases very
comparable to the effects of raptor-speciﬁc siRNAs. Accord-
ingly, we conclude mTORC2 to be a potent cell size regulator
and to be able to control cell size of cells in all phases of the
mammalian cell cycle.
mTORC2 is a major regulator of Akt kinase activity. One
Akt substrate that has been reported to be a pivotal regulator
of mammalian cell cycle and cell size is the tuberous sclerosis
gene product TSC2. Akt is known to regulate growth by
directly phosphorylating TSC2 (1,4,15–20). To investigate
whether TSC2 is essentially involved in the mTORC2-
mediated cell cycle and/or cell size regulation, we analysed
the effects of TSC2-speciﬁc siRNA treatment on the
rictor-siRNA-induced deregulations described above. Several
independent experiments revealed that the rictor-siRNA-
triggered accumulation of G0/G1 cells heavily depends on
the endogenous levels of TSC2. The same was found to be
true for the effects of rictor knockdown on the size of cells
in all different cell cycle phases.
In the past, different observations were reported regarding
the question whether mTORC2 affects the mTORC1-induced
phosphorylation of p70S6K. Very likely, owing to the usage
of different approaches to modulate mTORC2 and of different
transformed immortalized cells, modulating mTORC2 was
described to be either without any effects on p70S6K phos-
phorylation, or to trigger its up- or downregulation (31–33).
However, whenever we downregulated endogenous
mTORC2 activity via rictor-speciﬁc siRNAs in non-
transformed, non-immortalized primary human cells, we
observed a very pronounced downregulation of endogenous
mTORC1-mediated p70S6K phosphorylation on T389. This
is one observation that provides evidence for the mTORC1/
p70S6K cascade to be involved mTORC2-induced cell size
and cell cycle regulation. As discussed above, we proved
TSC2 to be of essential relevance for these mTORC2-
dependent regulations and TSC2 is very well known to exert
its cell size effects via regulation of mTORC1/p70S6K.
Knockdown of TSC2 reverted the cell cycle and cell size
effects of rictor-speciﬁc siRNAs accompanied with a reactiva-
tion of endogenous T389 p70S6K phosphorylation. In
addition, this ﬁnding shows that the effects of downregulated
mTORC2 activity on mTORC1 are indeed mediated via the
TSC2-involving cascade. Knockdown of PRAS40 could not
reactivate p70S6K phosphorylation and also did not have
any inﬂuence on the mTORC2-triggered cell size and cell
cycle effects.
All these ﬁndings provide strong evidence that mTORC2
affects cell size regulation via modulating the potential of
TSC2 to regulate mTORC1. This potential of TSC2 is
Human Molecular Genetics, 2009, Vol. 18, No. 17 3307known to be mediated via Rheb (1–4). We found that TSC2’s
potential to counteract mTORC2-mediated cell size control
indeed depends on functional Rheb. Taken together with our
here reported observation that downregulation of mTORC2
via rictor siRNAs cannot control mammalian cell size in
cells harboring constitutive Akt kinase activity, these ﬁndings
allow the conclusion that mTORC2 is a potent regulator of
mammalian cell size via a mechanism involving the Akt/
TSC2/Rheb cascade.
MATERIALS AND METHODS
Cell culture
IMR-90 (ATCC no. CCL-186) are non-transformed, non-
immortalized human diploid ﬁbroblasts from fetal lung and
have a ﬁnite lifetime being capable of attaining around 58
population doublings before the onset of senescence. They
were obtained from the American Type Culture Collection
at passage number 10 (population doubling 26) and were
grown in Dulbecco’s modiﬁed Eagle’s medium (DMEM) at
4.5 g/l glucose, supplemented with 10% calf serum and anti-
biotics (30 mg/l penicillin, 50 mg/l streptomycin sulphate) at
378C and 5% CO2. In the course of experiments, IMR-90
cells were grown for no more than eight additional passages
( 47 total population doublings) and were regularly analysed
by standard karyotyping to conﬁrm a normal diploid karyo-
type. For synchronization in G0/G1, IMR-90 were used at
passage number 15 and deprived of serum in medium contain-
ing 0.2% FCS for 48 h. Cells were stimulated to re-enter the
cell cycle by the addition of 10% serum for another 36 h.
Experiments involving the mTOR inhibitor rapamycin (Cal-
biochem) were performed in the absence (DMSO vehicle
control) or presence of the drug at ﬁnal concentrations as
indicated.
Transfections
Pooled short interfering RNAs (siRNAs) speciﬁcally targeting
human raptor, rictor, PRAS40, TSC2 or Rheb were purchased
from Dharmacon (ON-TARGETplus SMART pool reagents)
and were delivered to the cells at a ﬁnal range of 50–
100 nM using Lipofectamine 2000 reagent (Invitrogen) follow-
ing the transfection protocol provided by the manufacturer. A
pool of four non-targeting siRNAs was used as a control for
non-sequence-speciﬁc effects. In experiments where simul-
taneous knockdown of two or three genes was performed,
the overall amount of siRNA for each reaction was kept con-
stant by the addition of non-targeting siRNAs. Cells were tryp-
sinized, replated into fresh growth medium 48–60 hours
post-transfection and grown for another 20 h until harvest. In
some experiments siRNA-treated cells were grown for 72 h,
replated and retransfected with DNA using the following plas-
mids: pUSE-myr-Akt1 (activated Akt, N-terminal myristoyla-
tion, myc-tagged), pUSE empty vector (both purchased from
Millipore), GFP-spectrin expression vector. Transfections
with pUSE expression plasmids and GFP-spectrin plasmids
were performed with Lipofectamine 2000 at a ﬁnal ratio of
1:5. Cells were harvested for analysis 36 h later.
Flow cytometry
For cytoﬂuorometric DNA and cell size analyses, cells were
harvested by gentle trypsinization and ﬁxed by rapid submer-
sion in ice-cold 85% ethanol. After overnight ﬁxation at
2208C, DNA was stained in an appropriate volume of staining
solution containing 0.25 mg/ml propidium iodide, 0.05 mg/ml
RNase and 0.1% Triton X-100 in citrate buffer, pH 7.8. A total
of 1.5 10
4 to 3 10
4 cells per sample (in case of DNA trans-
fections 1 10
4 to 1.5 10
4 GFP-spectrin-positive cells per
sample) were collected in linear ampliﬁcation mode and ana-
lysed on a Beckton Dickinson FACScan using CELLQUEST
and MODFIT software. Cell size analyses via FSC were basi-
cally performed in two different ways as previously described
(12): overall cell size distribution, regardless of the different
cell cycle phases, was investigated via one-dimensional FSC
histograms. To enable direct comparison of different
samples, overlays of FSC histograms were performed. In
addition, mean FSC values, representing the average FSC dis-
tribution of the analysed cell pool, were obtained using CELL-
QUEST histogram statistical tools. Cell size distribution
according to the different cell cycle phases was analysed via
two-dimensional, so called contour blots of FSC versus
DNA content. Contour blots, representing a particular,
density-related presentation of two parameters in relation to
cell numbers, were generated in probability density mode at
20%, means the outermost contour line represents 10% of
the total number of events, the next contour represents 30%,
then 50%, 70% and 90%. Except contour blots shown in
Figure 2E, left panel, which are presented in linear density
mode and served as the template to gate G0/G1 and S þ G2/
M cells, all blots have been generated in the same way. To
visualize FSC shifts between blots of different samples, a
bar, or alternatively a crosshair, was set into the center of
the G0/G1 (2 N) population of control cells. Alternatively,
FSC overlays of G0/G1, S and/or G2/M gated populations
are presented.
Protein extraction and immunoblotting
Extracts of cellular total protein were prepared by physical
disruption of cell membranes by repeated freeze-and-thaw
cycles. Brieﬂy, cells were washed with PBS and harvested
by scraping. Pellets were lysed in buffer A containing
20 mM Hepes, pH 7.9, 0.4 M NaCl, 2.5% glycerol, 1 mM
EDTA, 0.5 mM DTT, 1 mM PMSF, 0.5 mM NaF, 0.5 mM
Na3VO4 supplemented with 2 mg/ml aprotinin, 2 mg/ml leu-
peptin, 0.3 mg/ml benzamidinchlorid, 10 mg/ml trypsin inhibi-
tor by freezing and thawing. Supernatants were collected by
centrifugation at 15 000 rpm for 20 min at 48C and stored at
2808C. Proteins were resolved using 10% SDS–PAGE and
transferred to nitrocellulose. Blots were stained with
Ponceau-S to visualize the amount of loaded protein (11).
For immunodetection antibodies speciﬁc for the following
proteins were used: tuberin C-20 (Santa Cruz, no. sc-893),
raptor clone 24C12 (Cell Signaling, no. 2280), rictor clone
53A2 (Cell Signaling, no. 2114), PRAS40 (Cell Signaling,
no. 2610), cyclin D1 M-20 (Santa Cruz, no. sc-718), cyclin
A H-432 (Santa Cruz, no. sc-751), phospho-p70S6 kinase
T389 clone 108D2 (Cell Signaling, no. 9234), p70S6 kinase
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clone D9E (Cell Signaling, no. 4060), Akt (pan) clone
C67E7 (Cell Signaling, no. 4691), Kip1/p27 clone 57 (Trans-
duction Laboratories, no. K25020), c-myc clone 9E10 (BD
Pharmingen, no. 554205) and a-tubulin (DM1A, Calbiochem,
no. CP06). Rabbit polyclonal and monoclonal antibodies were
detected using anti-rabbit IgG, a HRP-linked heavy and light
chain antibody from goat (no. A120-101P, Bethyl Labora-
tories); mouse monoclonal antibodies were detected using
anti-mouse IgG, a HRP-linked heavy and light chain antibody
from goat (no. A90-116P, Bethyl Laboratories). Signals were
detected using the enhanced chemiluminescence method
(Pierce). Some of the presented western blots were densitome-
trically analysed using LabWorks image acquisition and
analysis software. The results are given in relation to the
according control value set as 1.
Brdu incorporation assay and immunoﬂuorescence
The DNA Replication Assay Kit (Millipore) was performed
according to the manufacturer’s instructions. Brieﬂy, cells
were grown on coverslips, starved and restimulated as
described above, pulse-labeled for 60 min with 10 mM BrdU
and ﬁxed in 95% ethanol/5% glacial acetic acid. BrdU-
positive cells were detected using a monoclonal antibody
against BrdU and an Alexa Fluor 488 goat anti-mouse second-
ary antibody (no. A11029, Molecular Probes). For immunode-
tection of cyclin A, cells were ﬁxed in 4% paraformaldehyde
for 10 min at room temperature, treated with 0.1% Triton
X-100 for 15 min and blocked for non-speciﬁc binding in
PBS containing 3% BSA for another 30 min. After 1 h incu-
bation with anti-cyclin A antibody (H-432, Santa Cruz, no.
sc-751) cyclin A-positive cells were visualized by incubation
with Alexa Fluor 488 goat anti-rabbit IgG (no. A11034, Mol-
ecular Probes). Cell nuclei were counterstained with DAPI.
Fluorescence was analysed on a conventional microscope
equipped with a video camera and a ﬂuorescence attachment
(model Axioplan 2 imaging with FluoArc, Zeiss) using a Plan-
Neoﬂuor 40x oil immersion (NA 1.3) objective. MetaSystems
software was used for image acquisition and Adobe Photoshop
7.0 was used for further processing. At least 250 cells were
scored for each time point.
Statisical analyses
The signiﬁcance of the observed differences was determined by
Student’s t-test (paired, two-tailed) using Graph-Pad INSTAT
software. P-values . 0.05 are deﬁned as not signiﬁcant.
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